NEW YORK (GenomeWeb News) – Clontech Laboratories and Tet Systems said today they have expanded an existing licensing agreement to grant Clontech rights to develop, manufacture, and commercialize novel Tet products, including the Tet-On 3G Inducible Expression System.
In a statement, the two firms said that the new system offers highly inducible, sensitive control of gene expression and includes two novel components, including an improved transcriptional activator, which was developed by researchers at the Academic Medical Center at the University of Amsterdam, and a novel minimal Tet promoter developed at the University of Heidelberg.
The two firms said that the Tet-On 3G Inducible Expression System provides scientists greater control of gene expression regulation "due to lower expression in the non-induced state, even in transient transfection settings." It has 10-fold increased sensitivity for the inducing agent Doxycycline, expanding "the long-established benefits of dynamic transactivation, particularly for in vivo models," Clontech and Tet added.
Clontech will be launching a suite of the new systems, including promoters, fluorescent markers, and bicistronic systems on Aug. 2.
Terms of the amended agreement was not disclosed.